CORT
Corcept Therapeutics Incorporated. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website corcept.com
- Employees(FY) 299
- ISIN US2183521028
Performance
+5.6%
1W
+20.09%
1M
+23.69%
3M
+11.87%
6M
-13.52%
YTD
+14.93%
1Y
Profile
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Investment Analysis Report: CORT
Overview
In this investment analysis report, we will delve into a comprehensive analysis of CORT, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating ...
Technical Analysis of CORT 2024-05-10
Overview:
In analyzing the technical indicators for CORT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...
Recent News & Updates
- 2024-05-16 03:12
- 2024-05-13 07:01
- 2024-05-13 04:01
Pipeline Moves: Phase III completion for Corcept’s relaorilant(Clinical Trials Arena)
- 2024-05-03 06:48
Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-02 11:45
- 2024-05-02 10:48
- 2024-05-02 08:01
Q1 2024 Corcept Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-02 03:41
- 2024-05-01 23:45
- 2024-05-01 20:30
- 2024-05-01 17:50
- 2024-05-01 16:40
Corcept: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-01 16:05
- 2024-05-01 04:05
- 2024-04-29 08:00
Corcept Completes Enrollment in Phase 4 CATALYST Trial(GlobeNewswire)
- 2024-04-28 20:00
Corcept Completes Enrollment in Phase 4 CATALYST Trial(Globenewswire)
- 2024-04-24 16:05
- 2024-04-24 04:05
- 2024-04-23 20:00
CORT: Lowering target price to $18.00(Argus Research)
- 2024-04-23 12:12
- 2024-04-23 00:12
- 2024-04-22 08:00
- 2024-04-21 20:00
- 2024-04-17 12:00
- 2024-04-17 00:00
- 2024-04-16 11:34
- 2024-04-15 23:34
- 2024-04-15 08:00
- 2024-04-14 20:00
- 2024-04-09 11:09
Page 1 of 6
previousnext